Mass General Home


Principal Investigator Tracy Batchelor, M.D., Rrain Tumor Center
A Phase 2 Study of AZD2171 in Recurrent Glioblastoma
This is a phase 2 study of AZD2171 in patients with recurrent glioblastoma. Eligible patients must have archival paraffin-embedded tumor tissue from a prior resection available for analysis. In addition, eligible patients must have a Karnofsky Performance Score (KPS) of 60 or greater, can have received no more than 2 anti-neoplastic drugs as part of their prior treatment, must have contrast-enhancing tumor on MRI, must not have had tumor resection (or other forms of major surgery) within 90 days, must not have received any form of cranial radiation within the past 3 months and must be capable of providing informed consent.
Eligible patients will receive AZD2171 at a dose of 45 mg daily by mouth continuously. There is no maximal length of therapy.

Key Personnel